In all NSCLC patients receiving platinum-based chemotherapy/immunotherapy, poorer PFS and OS were observed in patients with BER pathway mutations and those with FANCG mutations (Fig. 5A, B, E, and F). The gene discussed is FANCG; the disease is non-small cell lung carcinoma.